A low white blood cell count or “neutropenia” is a condition characterized by abnormally low levels of neutrophils in the circulating blood. Neutrophils are a specific kind of white blood cell that help prevent and fight infections. The most common reason that cancer patients experience neutropenia is as a side effect of chemotherapy. Chemotherapy-induced neutropenia increases a patient’s risk of infection and disrupts cancer treatment. Fortunately, neutropenia can be prevented through the use of white blood cell growth factors. The prevention of neutropenia allows patients to receive their scheduled treatment and reduces the risk of infection and hospitalization.
- What is neutropenia?
- Why is chemotherapy-induced neutropenia important?
- How is neutropenia diagnosed?
- Can neutropenia be prevented?
- What treatments are administered to prevent neutropenia?
- What are the strategies to improve treatment?
Neutropenia is a condition characterized by abnormally low blood levels of infection-fighting neutrophils, a specific kind of white blood cell. Neutropenia increases your risk of bacterial and fungal infections.
The most common reason that cancer patients experience neutropenia is as a side effect of chemotherapy. Chemotherapy involves the use of drugs to destroy cancer cells. Chemotherapy works by destroying cells that grow rapidly, a characteristic of cancer cells. Unfortunately, chemotherapy also affects normal cells that grow rapidly, such as blood cells in the bone marrow, cells in the hair follicles, or cells in the mouth and intestines. Chemotherapy-induced neutropenia typically occurs 3-7 days following administration of chemotherapy and continues for several days before neutrophil levels return to normal. The type and dose of chemotherapy affects how low the neutrophil count drops and how long it will take to recover.
Infrequently, cancer patients may also experience neutropenia from other medications or as a consequence of their underlying cancer. When discussing the consequences and management of neutropenia, it is important to distinguish between chemotherapy-induced neutropenia and neutropenia resulting from other causes because they may be managed differently.
While receiving chemotherapy, you will frequently have your complete blood count (CBC) checked to determine whether you have enough neutrophils. Typically there are billions of neutrophils in the blood; however, certain chemotherapy drugs will lower the neutrophil count. When a doctor or nurse discusses CBC test results, they frequently refer to the “absolute neutrophil count” (ANC) or the number of neutrophils in the patient’s blood. A “low white blood count” is another common term used to describe a low neutrophil level in the blood. Fortunately, having a low level of neutrophils can be corrected.
Chemotherapy-induced neutropenia is important because it may:
- Increase your risk of life-threatening infection.
- Disrupt delivery of your cancer treatment, resulting in a change to the planned dose and time.
The fewer the neutrophils in the blood and the longer you remain without enough neutrophils, the more susceptible you are to developing a bacterial or fungal infection. Neutrophils are a major component of antibacterial defense mechanisms. As the neutrophil count falls below 1.0, 0.5, and 0.1 x 109/L, the frequency of life-threatening infection rises steeply from 10% to 19% and 28%, respectively. If you develop a fever during neutropenia you may require treatment with intravenous antibiotics and admission to the hospital until the number of neutrophils in the blood returns to sufficient levels to fight the infection.
Another reason neutropenia is important is that, in some cases, it can be severe enough that your chemotherapy treatment may need to be delayed or dose reduced, which reduces some patients’ chance for cure. When you are treated with chemotherapy, it is for the purpose of destroying cancer cells in order to reduce symptoms from your cancer, prolong your survival or increase your chance of cure. The dose and time schedule of chemotherapy drugs administered have been scientifically determined to produce the best chance of survival or cure. If you develop neutropenia, your doctors may have to delay your treatment or reduce the doses of your chemotherapy until your neutrophil counts have recovered. Clinical studies have shown that, for certain cancers, reducing the dose of chemotherapy or lengthening the time between treatments lowers cure rates compared to full-dose, on-time treatment. Fortunately, there are strategies for the prevention of chemotherapy-induced neutropenia that have been proven to reduce the incidence of fever, infection, admission to the hospital and allow you to receive your treatment on schedule.
Who is at a higher risk for chemotherapy-induced neutropenia?
- Patients receiving chemotherapy that decreases the number of white blood cells
- Patients who already have a low white blood cell count, or who have previously received chemotherapy or radiation treatment
- Patients age 70 and older who may be at risk of more severe infection and longer hospitalizations
- Patients with other conditions affecting their immune system
Chemotherapy-induced neutropenia can be prevented in most patients with the use of white blood cell growth factors. Blood cell growth factors are naturally occurring substances called cytokines that regulate certain critical functions in the body. They are responsible for stimulating cells in the bone marrow to produce more blood cells.
The white blood cell growth factors approved by the U.S. Food and Drug Administration for the prevention of chemotherapy-induced neutropenia are Neupogen® (filgrastim) and Neulasta® (pegfilgrastim).
The reduction in the frequency and severity of neutropenia and its associated complications has resulted from scientists developing a better understanding of the basic biology of bone marrow blood cell production and from participation in clinical trials designed to evaluate strategies directed at reducing neutropenia and its complications. Currently, there are several areas of active investigation aimed at improving the prevention and management of neutropenia.
Peripheral blood stem cells: Stem cells responsible for the production of neutrophils can be collected in large quantities from the peripheral blood. Delivery of peripheral blood stem cells following very high doses of chemotherapy has been demonstrated to result in more rapid neutrophil recovery than with stem cells collected from bone marrow. Many doctors have begun evaluating the use of peripheral blood stem cells to support multiple cycles of dose intensive chemotherapy alone or in combination with Neulasta® or other blood cell growth factors for the purpose of reducing the frequency and severity of neutropenia and its complications.
Ex vivoexpansion: Stem cells responsible for the development of neutrophils can be removed from a patient’s body and grown or expanded in the laboratory. When large numbers of neutrophils have been grown in the laboratory, they can be infused into a patient to support delivery of chemotherapy with the goal of preventing neutropenia. The process of ex vivo expansion is currently being evaluated in clinical trials at some centers around the country.